Roche Ups Negotiating Ante With Hostile Bid For Genentech
Executive Summary
By making a hostile bid for Genentech at a lower price, Roche is trying to address at least two important concerns in one blow: uncertainty over upcoming results of a key clinical trial for the blockbuster Avastin cancer medication and offsetting potentially higher financing costs needed to ink the deal due to the troubled economic climate
You may also be interested in...
ATLAS Phase III Data Point Avastin/Tarceva Combo In Positive Direction
Phase III results using an Avastin and Tarceva combination in non-small cell lung cancer could mean FDA will not insist on survival data before approving Tarceva's supplemental NDA in first-line maintenance non-small cell lung cancer. Genentech disclosed results from the ATLAS trial Feb. 2
ATLAS Phase III Data Point Avastin/Tarceva Combo In Positive Direction
Phase III results using an Avastin and Tarceva combination in non-small cell lung cancer could mean FDA will not insist on survival data before approving Tarceva's supplemental NDA in first-line maintenance non-small cell lung cancer. Genentech disclosed results from the ATLAS trial Feb. 2
Former FTC Economists Question TARP Funding Behind Pfizer-Wyeth Deal
In reviewing the proposed Pfizer-Wyeth merger, the Federal Trade Commission should take into account that the deal would indirectly be financed with government bail out money that banks could better spend elsewhere to stimulate the economy, two former FTC chief economists recommend